Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of TQB2930 with chemotherapy with or without bevacizumab in HER2-abnormal advanced colorectal cancer
CTR20262358Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2930 in colorectal cancer (CRC), sponsored by Nanjing Shunxin Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
TQB2930
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20262358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262358.